Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.50 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15612826 | 0.83 | TGFBR1 (0.53) | FOLH1NAALAD2RIMKLALMNAMEN1 | |
| SCHEMBL13753737 | 0.82 | FOLH1 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL24455554 | 0.82 | FOLH1 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15592826 | 0.82 | ALDH1A1 (0.63) | FOLH1NAALAD2RIMKLALMNAMEN1 | |
| SCHEMBL21335970 | 0.79 | CA1 (0.34) | KMT2A | |
| SCHEMBL468749 | 0.78 | SMN1; SMN2 (0.59) | FOLH1NAALAD2RIMKLAALDH1A1MAPT | |
| SCHEMBL468750 | 0.78 | SMN1; SMN2 (0.59) | FOLH1NAALAD2RIMKLAALDH1A1MAPT | |
| SCHEMBL5125262 | 0.78 | FOLH1 (0.47) | FOLH1NAALAD2RIMKLALMNAMEN1 | |
| SCHEMBL4745785 | 0.78 | — | — | |
| SCHEMBL21621515 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | FOLH1 2667/4885NAALAD2 3363/4885RIMKLA 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.